Tandem’s t:slim X2 Insulin Pump Now with Control-IQ Auto Dosing
The FDA has simply cleared the primary clever insulin pump that may mechanically administer correction boluses along with regulating insulin to stop low and high blood sugar ranges. Tandem Diabetes’ up to date t:slim X2 insulin pump works with Dexcom’s G6 steady glucometer and contours Tandem’s new Control-IQ era that is helping to ensure that sufferers with diabetes keep throughout the really useful 70-180 mg/dL vary up to imaginable.
Patients who’ve an present t:slim X2 that’s nonetheless beneath guaranty can opt-in to obtain a unfastened device replace that may let them benefit from Control-IQ. This replace will have to be to be had someday in January of subsequent 12 months.
Control-IQ depends upon the measurements received from the Dexcom G6, alongside with wisdom about how a lot insulin it is aware of it already delivered, to appropriately expect sugar ranges a few part hour into the longer term. Based on that, the machine adjusts how a lot insulin to supply, and if the prediction is especially prime (over 180 mg/dL), Control-IQ kicks in to calculate how a lot bolus to manage to get the worth right down to 110 mg/dL. It then asks the pump to manage 60 % of that quantity each and every hour till glucose within the blood drops considerably.
Patients can inform the pump about actions they plan on doing, together with sound asleep and workout, in order that it takes that into account and gives suitable insulin doses.
“Not only do new closed-loop systems need to be effective at improving glycemic control, they must also be easy to understand and use so patients can experience the full benefits of the technology,” stated Boris Kovatchev, PhD, Director of the Center for Diabetes Technology on the University of Virginia and predominant investigator of the International Diabetes Closed Loop (iDCL) trials, in a press unencumber. “The t:slim X2 insulin pump with Control-IQ technology successfully achieved both objectives in clinical studies. We are very proud of the extensive academic research that went into this effort, and we are thrilled to see this work has translated into an FDA-cleared device for clinical use so that more people can experience the benefits of this technology.”
“With this clearance, we will be launching the most advanced automated insulin dosing system commercially available in the world today,” added John Sheridan, president and CEO of Tandem Diabetes Care. “This is a testament to our commitment to improving the lives of people with diabetes by offering simple-to-use products that deliver superior performance.”
Info web page: Control-IQ Technology